In vitro antifungal activity of N,N-phenyl-1,2,3,4-thiatriazole-5-yl-2,4-beta-resorcylcarbothioamide.
The aim of this study was the determination of the antifungal activity of N,N-phenyl-1,2,3,4-thiatriazol-5-yl-2,4-beta-resorcylcarbothioamide (PTR) against Candida albicans, non-albicans Candida species, dermatophytes and moulds and of its influence on the enzymatic activity of C. albicans strains. The reference strains C. albicans ATCC 10231, 200 of C. albicans strains, 7 of non-albicans C. species, 12 dermatophyte strains and 20 mould strains were isolated from different patients. The mean minimum inhibitory concentration (MIC) of PTR against C. albicans strains isolated from patients was 19.6 mg/l, for reference C. albicans ATCC 10,231 it was 12.5 mg/l on Sabouraud's medium (SB). The mean MIC of isolates from patients was 16.9 mg/l, and reference strains 6.25 mg/l on YNB medium, respectively. The MIC of PTR against 7 non-albicans C. species was 27.7 mg/l on SB and 15.6 mg/l on YNB, respectively. The mean MIC of PTR against C. albicans strains isolated from patients was 14.9 mg/l, C. albicans ATCC 10,231 6.25 mg/l and non-Candida species strains 14 mg/l on RPMI medium. The MICs of PTR against dermatophytes ranged from 3 to 25 mg/l. The MICs of PTR against moulds were 25 mg/l and 100 mg/l, respectively. PTR inhibited the enzymatic activity of selected hydrolases of C. albicans and non-Candida species strains. PTR exerts a potent antifungal activity against the yeast-like fungi strains, moulds and dermatophytes. This new compound inhibited the enzymatic activity of selected hydrolases.
Krajewska-Kułak
Elzbieta
E
Mycological Laboratory of the Department of General Nursing, Medical University of Białystok, Poland.
Niewiadomy
Andrzej
A
Łukaszuk
Cecylia
C
Matysiak
Joanna
J
Kostecka
Małgorzta
M
D000935:Antifungal Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D003883:Arthrodermataceae / Q000187:drug effects / Q000201:enzymology; D002176:Candida albicans / Q000187:drug effects / Q000201:enzymology; D015725:Fluconazole / Q000494:pharmacology; D005658:Fungi / Q000187:drug effects* / Q000201:enzymology; D007202:Indicators and Reagents; D017964:Itraconazole / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008826:Microbial Sensitivity Tests; D012118:Resorcinols / Q000138:chemical synthesis* / Q000494:pharmacology*; D013871:Thiones / Q000138:chemical synthesis* / Q000494:pharmacology*
D000935:Antifungal Agents; D007202:Indicators and Reagents; C478821:N-phenyl-1,2,3,4-thiatriazol-5-yl-beta-resorcylcarbothioamide; D012118:Resorcinols; D013871:Thiones; D017964:Itraconazole; D015725:Fluconazole